Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (NCT07108998)

🧪 Interventions in This Study

• Epcoritamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• University of Cincinnati — Cincinnati, Ohio

📞 Contact the Study Coordinator

Phone: (513) 584-7698

Email: cancer@uchealth.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in CLL/SLL

• Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — Duarte, California
• Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — Durham, North Carolina
• Global Trial in APG2575 for Patients With CLL/SLL — Tuscon, Arizona
• Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL — Duarte, California

Explore by condition: All CLL/SLL clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.